Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics, Inc. (AVTX)
:AVTX
AVTX Stock Chart & Stats
$18.91
-$0.55(-7.32%)
At close: 4:00 PM EST
$18.91
-$0.55(-7.32%)
Day’s Range― - ―
52-Week Range$3.39 - $20.72
Previous CloseN/A
Volume10.82K
Average Volume (3M)351.18K
Market Cap
$349.08M
Enterprise Value$68.79M
Total Cash (Recent Filing)$111.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 26, 2026EPS Estimate
-1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding18,133,968
10 Day Avg. Volume302,630
30 Day Avg. Volume351,182
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)136.95
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue358.30
Enterprise Value/Gross Profit655.18
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$37.40Price Target Upside97.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAVTX-009's strong positioning for a positive Phase II readout in hidradenitis suppurativa enhances its clinical potential.
Competitive AdvantageAVTX-009 is believed to have a comparable or even better IL-1 pathway inhibition compared to lutikizumab, indicating a potential competitive edge.
Financial PerformanceA blended approach using discounted cash flow valuation and a 2036 P/E multiple suggests promising financial potential for AVTX-009 in the long term.
Bears Say
Development RisksRisks include potential delays in clinical development and negative clinical data.
Market AdoptionThere is a risk of slower-than-anticipated commercial uptake of AVTX-009.
Regulatory ApprovalConcerns exist over the failure to achieve approval for AVTX-009.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was $3.39 and its highest was $20.72 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is $349.08M.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 97 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$2.19 earnings per share for the quarter, missing the consensus estimate of -$1.658 by -$0.532.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -1.37.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 18,133,968 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -$2.19 in its last earnings report, missing expectations of -$1.658. Following the earnings report the stock price went down -6.261%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.40 (97.78% Upside)
$37.40 (97.78% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 270.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 14.9%
Last 30 Days ▼ 14.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.77%
12-Months-Change
Fundamentals
Return on Equity
-174.79%
Trailing 12-Months
Asset Growth
27.06%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$37.40
▲(97.78% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―